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Abstract
Background: The use of somatic mutations for predicting clinical outcome is difficult because a mutation can
indirectly influence the function of many genes, and also because clinical follow-up is sparse in the relatively young
next generation sequencing (NGS) databanks. Here we approach this problem by linking sequence databanks to
well annotated gene-chip datasets, using a multigene transcriptomic fingerprint as a link between gene mutations
and gene expression in breast cancer patients.
Methods: The database consists of 763 NGS samples containing mutational status for 22,938 genes and RNA-seq
data for 10,987 genes. The gene chip database contains 5,934 patients with 10,987 genes plus clinical
characteristics. For the prediction, mutations present in a sample are first translated into a ‘transcriptomic
fingerprint’ by running ROC analysis on mutation and RNA-seq data. Then correlation to survival is assessed
by computing Cox regression for both up- and downregulated signatures.
Results: According to this approach, the top driver oncogenes having a mutation prevalence over 5 %
included AKT1, TRANK1, TRAPPC10, RPGR, COL6A2, RAPGEF4, ATG2B, CNTRL, NAA38, OSBPL10, POTEF, SCLT1,
SUN1, VWDE, MTUS2, and PIK3CA, and the top tumor suppressor genes included PHEX, TP53, GGA3, RGS22,
PXDNL, ARFGEF1, BRCA2, CHD8, GCC2, and ARMC4. The system was validated by computing correlation
between RNA-seq and microarray data (r2 = 0.73, P < 1E-16). Cross-validation using 20 genes with a prevalence
of approximately 5 % confirmed analysis reproducibility.
Conclusions: We established a pipeline enabling rapid clinical validation of a discovered mutation in a large
breast cancer cohort. An online interface is available for evaluating any human gene mutation or
combinations of maximum three such genes (http://www.g-2-o.com).
Background
Tumor evolution involves the accumulation of muta-
tions during tumorigenesis enabling acquisition of the
well-known hallmarks of cancer [1]. Current anticancer
therapy presupposes a direct connection between muta-
tional status and phenotype, therefore clinical decisions
are often directly based on the genotype. For instance,
KRAS status is considered an indicator of a patient’s
response to the EGFR inhibitor panitumumab [2] and
BRAF V600E status is used to predict response to the
BRAF inhibitor vemurafenib [3]. However, such direct
associations are not consistent among different clinical
cohorts. For instance, vemurafenib was effective in
BRAF V600E mutant melanoma but had no activity in
BRAF V600E mutant colon cancer [4]. Similarly, mTOR
and PI3K inhibitors have the same activity in PI3K
mutant and normal breast tumors [5]. Also, the recently
approved CDK4/6 inhibitor palbociclib had the same
level of activity in breast tumors harboring altered and
normal CDK4/6 [6].
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The first NGS studies of breast cancer (BC) identified
only three genes mutated in more than 10 % of BC tu-
mors: TP53 (mutation rate 40 % of tumors), PI3K (25 %
of tumors), and GATA3 (10 % of tumors). In particular,
the most important genes identified in 100 primary
breast cancers included AKT1, BRCA1, CDH1, GATA3,
PIK3CA, PTEN, RB, TP53, ARID1B, CASP8, and
MAP3K1 [7]. Banerji and coworkers studied 103 BC pa-
tients with NGS and recognized AKT1, PIK3CA,
GATA3, TP53, and MAP3K1 as the most significant
genes [8]. In the TCGA project, the most prevalent mu-
tations hit PIK3CA, PTEN, AKT1, TP53, GATA3,
CDH1, RB1, MLL3, MAP3K1, and CDKN1B [9]. Ellis
and associates performed NGS on biopsies from two
neoadjuvant aromatase inhibitor clinical trials and found
PIK3CA, TP53, GATA3, CDH1, RB1, MLL3, MAP3K1,
and CDKN1B to be the primary genes affected [10].
Despite differences in study design, these studies have
a few common messages. First of all, NGS for a few hun-
dreds of breast tumors has revealed new cancer genes.
Additionally, NGS allowed the survey of intratumoral
heterogeneity and has shown that there was always a
dominant clone comprising at least 50 % of the tumor
cells [11]. Therapeutically targeting the driver genetic
aberrations will have the most significant effect on this
clone. Targeted NGS in primary and metastatic breast
cancers revealed that almost 85 % of tumors have a gen-
etic aberration in a gene which is already actionable [12].
We must, however, note that some of the most import-
ant genes including TP53 and KRAS are not yet directly
targetable.
The relationship between somatic mutations and clin-
ical outcome is multi-layered, complex, and to a large
extent unknown, therefore the assumption of a direct in-
fluence of genotype on phenotype is a key limitation in
the generally accepted paradigm. An empirical analysis
to associate sequence variations to outcome would need
thousands of patients with sufficient follow up to be se-
quenced with next generation sequencing (NGS) tech-
nologies. We are far from this desirable goal. For
instance, among the patients included in the Cancer
Genome Atlas (TCGA) [13] – the largest breast cancer
NGS database available today – approximately 89 % of
the patients are censored. While one can expect fewer
events because TCGA reports overall survival only, but
this is coupled with a median follow up of merely
1.3 years.1 Thus, the paucity of clinical annotation of the
TCGA and other mutation datasets makes direct testing
of the prognostic impact both limited and underpowered
especially if one is interested in survival differences in
selected sub-cohorts of patients.
Here we propose an approach that could circumvent
this limitation. We postulate that a somatic mutation
perturbs not only the mutated gene but the perturbation
will propagate to a network of functionally related genes
from the same or other cellular pathways. As a result,
the effect of the mutation will be leveraged by a set of
genes, and the changes in the expression of these genes
that we term a ‘transcriptomic fingerprint’ can be used
as a surrogate marker of the mutation status (Fig. 1).
Naturally, the genes indirectly affected by a mutation
are unknown, but can be inferred by statistical means if
there are sufficient data available. As we have recently
shown, genome-wide transcriptomic analysis across all
genes can identify genes affected by a given mutation
[14]. In brief, a large number of patients with known
genotype are divided into two cohorts (those with muta-
tions in a given gene or wild type), and transcripts associ-
ated with mutational status are identified by ROC analysis
across all genes. These genes can then be evaluated for
correlation with clinical outcome including therapy re-
sponse [14].
In the present work we extend this analysis to predict
the probability of patient survival from mutational data
of breast cancer patients. As already mentioned, there is
a growing body of samples with both mutation and gene
expression data, but only a few datasets include relapse
events on the same patients. At the same time, micro-
array (gene chip) data have been collected that have sub-
stantially longer follow up times and extensive clinical
annotations. Harvesting the combined prognostic value
of these two kinds of data is a challenging task with a
potential for exceptional clinical relevance. Here, our
aim was to combine available genotype and RNA-seq
data generated by NGS with gene expression data gener-
ated by gene chips, in order to develop a tool that could
estimate the complex prognostic impact of a genomic
anomaly. We believe that this method and the associated
online tool can be used to prioritize genes for further
functional study.
Methods
We implemented an approach to predict survival by sim-
ultaneously using gene mutation status and gene expres-
sion data. Main steps of the algorithm termed G-2-O
(genotype to outcome) involve splitting TCGA samples
into two cohorts using mutation status of the gene(s), then
identifying differentially expressed genes between these
cohorts using ROC analysis, and rendering a survival ana-
lysis using an independent dataset established using gene
chip data. The entire statistical pipeline is summarized in
Fig. 2 and the individual steps as well as database con-
struction are described below. An online interface for the
G2O algorithm is available at http://www.g-2-o.com.
NGS data download
Whole exome sequencing data and RNA-seq data for
breast cancer patients were obtained from The Cancer
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Genome Atlas (TCGA) of the National Cancer Institute
(http://cancergenome.nih.gov/) [13]. The aligned TCGA
datasets were downloaded from the CGHub repository
(website: https://cghub.ucsc.edu/) using the CGHub
download client software GeneTorrent (version 3.8.5) for
both tumor samples and matched normal samples (total
n = 1,526).
Mutation calling
Mutation calling and annotation was done with MuTect
[15] using default parameters. The human reference
genomes GRCh37, GRCh37-lite, and HG19 used for mu-
tation calling were downloaded according to the CGHub
websites’ ‘Reference Assemblies’ guideline (available at
https://browser.cghub.ucsc.edu/help/assemblies). To re-
duce the total number of mutations, we only accepted
somatic mutations that were labeled as ‘KEEP’ according
to the MutTect judgment algorithm, and were present in
at least four reads with a minimum of 20-fold read
coverage. Our rationale behind the selection of a lower
stringency threshold was intra-tumor heterogeneity, that
is, the presence of multiple, genetically diverse clones in
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Fig. 1 Complex effects of a single mutation. A cornerstone of our model is the leveraged effect of gene regulation network influencing the final
consequence of a mutation. Some target genes will be suppressed while others will be amplified resulting in a markedly changed transcriptomic
fingerprint for important genes
Fig. 2 Overview of the analysis setup. Mutation status and gene expression levels obtained from the TCGA repository are compared using ROC
analysis to identify a gene expression signature for each mutation. Then, the ability to predict survival for this signature is assessed in the gene
chip dataset. The entire analysis can be made for a single gene or for up to three genes together
Pongor et al. Genome Medicine  (2015) 7:104 Page 3 of 11
a single tumor which may affect tumor growth and pa-
tients survival. During treatment minor clones can also
have a prominent effect on the patients’ response to
therapy and survival [16]. Finally, the identified muta-
tions were annotated with MuTect using the dbSNP
(build 139) and COSMIC (version 68) databases [17].
Hit annotation
The identified sequence variations were functionally an-
notated using SNPeff v3.5 [18]. The reference databases
used with SNPEff were downloaded with the SNPeff
downloader. SNPeff is capable of annotating VCF files
generated by MuTect. The annotation generated two
outputs including a functionally annotated VCF file and
a list containing all the genes and the effect the muta-
tions had on the genes. The applied filters for the ‘Func-
tion class’ were: coding non-synonymous, stop gain,
coding synonymous, locus region of gene, and splice site.
The complete gene list comprising of n = 22,938 genes
from SNPeff was used during the functional annotation
(see Additional file 1: Table S1).
Processing of copy number variations
Copy-number variation (CNV) data were downloaded
from the TCGA repository on 1 February 2015. The
CNV data were filtered according to two parameters: at
least 10 probes had to be present at a position with a
segment mean above 0.2 for amplification, and under
−0.2 for deletions, as suggested in [19]. The filtered seg-
ments were annotated using the Human Gene Sets GTF
annotation file downloaded from the Ensembl database
of the Human Genome version GRCh37.
Processing of RNA-seq data
RNA-seq data for breast cancer patients was obtained
from the TCGA repository for the same patients who
also had mutation data. We downloaded the pre-
processed level 3 data generated using the Illumina
HiSeq 2000 RNA Sequencing Version 2 platform. Ex-
pression levels for these samples were determined using
a combination of MapSplice and RSEM. Individual pa-
tient files were merged into a single database using the
plyr R package [20].
Gene chip data
Set-up of microarray-database using GEO and EGA-
available microarray datasets was established as described
previously [21]. The entire breast cancer gene chip data-
base contains 5,934 patients. The raw Affymetrix .CEL
files were MAS5 normalized in the R v3.0.2 statistical en-
vironment (http://www.r-project.org) using the Affy Bio-
conductor library. We selected MAS5 for normalization
because it performed among the top normalization
methods compared to RT-PCR measurements in our
previous project [22]. Array quality control was computed
as described previously [23]. For each gene, the most reli-
able probe set was selected using JetSet [24].
Validation dataset
As a starting point of our analysis, we wanted to confirm
the correlation between the Affymetrix microarray and
Illumina RNA-seq platforms. For this purpose, we used
the TCGA lung squamous cell carcinoma dataset
(LUSC), because it contains matched RNA-seq and
Affymetrix gene chip data on the same samples. A
matched gene list comprising 10,987 genes was prepared
and pre-processed as described above for the breast can-
cer datasets. For each gene, we used the Spearman rank
correlation to compare RNA-seq and gene-chip based
expression levels. The correlation and a P value were
calculated R using the rcorr function of the Hmisc pack-
age (http://biostat.mc.vanderbilt.edu/wiki/Main/Hmisc).
G-2-O algorithm
The first step of the algorithm involves assigning each
sample to one of two cohorts based on the mutation sta-
tus of the investigated gene. Generally, the type of DNA
mutation used to split the samples can be any alteration
in the gene. As an output of this step a binary vector
termed ‘mutation pattern’ is calculated. In this, affected
samples are represented by a ‘1’ and unaffected samples
are represented as ‘0’.
In certain settings one might be interested in a custom
selection of gene variations – we performed such an
analysis to compare mutations resulting in altered
mRNA sequence (including start gain, exon, splice site,
non-synonymous coding, stop gain, and stop loss muta-
tions) to silent mutations (including mutations in in-
trons and synonymous coding mutations). In the final
analysis interface we enabled the user to custom-select a
combination of the alterations.
The next step is categorizing genes whose expression
is different between the two cohorts designated in the
previous step. For this, a univariate receiver operating
characteristic (ROC) analysis is separately performed
using the expression values of each gene. In other words,
samples are compared based by the previously identified
‘mutation pattern’ and significantly altered genes are se-
lected based on the area under the curve (AUC) value,
and the associated P value computed in the ROC ana-
lysis. The AUC value is calculated by the ROCR package
using the prediction() and performance() functions. The
G2O algorithm calculates the P values where the null
hypothesis is that the AUC value equals to 0.5. First, the
script calculates the standard error of the null hypothesis
[25] from which the function derives the z-score. The P
value is then calculated by transformation of the z-score
using the normal distribution. Only genes passing both
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AUC and P value thresholds are considered significant.
The final output of this step is a list of up- and downreg-
ulated genes whose expression is significantly associated
with the given genotype alteration of the original input
gene.
The final step involves the calculation of survival in
the gene chip database using the ‘metagenes’ selected in
the TCGA data – the average expression of the set of
significant genes identified by the ROC analysis are des-
ignated as the ‘metagene’ for the given genotype. This
survival analysis is therefore independent from the geno-
type and RNA-seq data.
We then assessed the correlation with survival for
each metagene using Cox proportional hazards regres-
sion and by plotting Kaplan-Meier survival plots for
median-dichotomized metagenes. In each analysis, meta-
genes for up- and downregulated gene sets are treated
separately resulting in two survival analyses for each
genotype (up- and downregulated genes in tumors hav-
ing a mutation of the gene).
Statistical packages utilized in the G-2-O algorithm
The ROC analysis is performed using the ROCR [26]
Bioconductor (http://www.bioconductor.org/) library in
the R statistical environment (http://www.r-project.org).
The AUC values are calculated automatically by the
ROCR package using the prediction() and performance()
functions. By default, a significance threshold of 0.01
and a minimal AUC of 0.65 are required for each gene
to be considered as significant. Cox regression analysis is
executed with the ‘survival’ R package version 2.38
downloaded from CRAN (http://CRAN.R-project.org/
package=survival). The Kaplan-Meier plots are generated
using the ‘survplot’ R package developed by Aron Eklund
(http://www.cbs.dtu.dk/~eklund/survplot/). Threshold for
statistical significance in the survival analysis was set
at P <0.05 and average HR >1.4 (average HR is based
on the mean of HR in the cohort having a higher HR
and 1/HR of the cohort having a lower HR value). In
the entire analysis pathway, none of the samples in-
volved in the training (ROC analysis) are included in
the test (survival analysis) as well.
Permutation test and random holdout
To assess the robustness of the results, we performed
the entire analysis 100× with 100 randomly selected
genes in each run and counted the number of significant
results. To assess the false positive rate, we plotted the
number of significant genes against the number of runs
delivering the given number of significant genes.
In a second cross-validation analysis set up to estimate
the reproducibility of the results, we excluded 20 % of
the samples at random and re-ran the entire analysis 10
times for a set of 20 selected top driver candidate genes.
We derived the average P value as well as the standard
deviation of all analyses for the given gene. Up- and
downregulated gene sets were treated separately in this
analysis.
Results
Database setup
Central to our approach is the joint analysis of three
breast cancer datasets, including somatic mutations and
RNA-seq gene expression from the TCGA project and
microarray and detailed survival data for a separate large
cohort of breast cancer patients. Mutations were identi-
fied in 20,938 genes in 763 patients. RNA-seq expression
data for 10,987 genes was also available for the same tu-
mors - only genes also present in the gene chips were
utilized to facilitate translation between the two plat-
forms. The microarray data for the matched 10,987
genes, and detailed follow-up including survival were
available for 5,934 patients from 39 independent breast
cancer datasets.
Comparison of RNA-seq and gene chip data
A total of 129 LUSC patients had matched RNA-seq and
microarray data. In these, Spearman correlation was
computed across all genes within each patient separately,
the median correlation was 0.73 with a P value <1E-16.
The coefficient was higher than 0.68 in all cases, indicat-
ing a robust correlation. Thus, we concluded that the
planned utilization of gene chips as a surrogate of RNA-
seq data is a feasible strategy for our analysis.
Analysis interface
We have set up an integrated web server that takes a
few user-selected genes as input. Then, it: (1) looks up
somatic mutations in the gene(s); (2) computes the com-
bined transcriptional fingerprint of the mutation(s) using
ROC analysis of breast cancer RNAseq data; and (3) uses
the top up and down metagenes to estimate patient sur-
vival using Cox regression on gene chip data. An im-
portant element is estimation of the transcriptional
signature for each somatic mutation, which is carried
out by ROC analysis on the mutation and RNA-seq data.
The output includes Kaplan-Meier plots for both up-and
downregulated signatures. As an example, see Fig. 3 for
the gene RFC1.
Mutation landscape of the training database
We compared the output generated by our mutation de-
tection method derived from the raw exome sequencing
data to previously reported common mutations in breast
cancer. Here we omitted any post-processing to truly as-
sess the established pipeline without the influence of
confounding additional steps. The computed mutation
prevalence for the known cancer genes overlapped with
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those of previous studies. We listed the top 20 cancer-
related and non-cancer-related genes in Table 1. Genes
listed in the COSMIC database [17] were designated as
cancer-related.
Comparison of mutation calling results to the published
TCGA data
Since our method using MuTect identified more mu-
tations than the available mutations downloaded from
the publicly available TCGA Data Matrix repository
(https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm),
we performed a mutation comparison between our results
and the downloaded TCGA MAF files. Our mutation call-
ing and annotating pipeline identified a significantly
higher number of mutations (mean ± standard deviation
of identified alterations by MuTect: 644 ± 69/sample and
TCGA: 102 ± 14/sample), which spawn from (1) lower
coverage threshold; (2) lower mutation frequency thresh-
old; (3) mutation annotation with snpEff generated multi-
gene annotations; and (4) we accepted mutations that
were found either in intronic or upstream regions of a
gene.
While the TCGA processing using a consensus call of
three different centers was set up to achieve high true
positive rate, the proportion of false negatives may also
be high. On the contrary, while MuTect identified more
somatic mutations, only 16 % of these fall into gene cod-
ing regions (usually with lower coverage and/or muta-
tion frequencies). The majority (84 %) of mutations
identified were either found in introns, or upstream
regions of a gene. When examining the 10 genes with
the highest prevalence in the TCGA MAF files, the
differences in prevalence compared to the MuTect
mutation calling were minimal (see Additional file 2:
Table S2). To validate MuTect results, we visualized a
few examples in the IGV Browser [27] (see Additional
file 3: Figure S1a–f ). When evaluating the entire set of
all single nucleotide variations across all 763 samples,
our analysis pipeline identified 1,636 of the 1,752 alter-
ations published in the TCGA repository, which trans-
lates to an intersection of 93 %.
Identification of strongest driver genes
To focus on genes with high clinical relevance, we aimed
to identify the strongest driver gene candidates. These
analyses were run by accepting an AUC value over 0.65
and a P value below 0.01 as significant in the ROC
analysis and accepting a HR over 1.4 and a P value
below 0.01 in the survival analysis. The complete ana-
lysis results for both up- and downregulated genes
sets for each of these 176 genes are listed in Additional
file 4: Table S3 and the 20 best performing genes based on
the computed HR are listed in Table 2. The complete set
of all genes included in the metagenes for each of these
drivers is listed in Additional file 2: Table S2.
To compare our results to more stringent mutation
calling criteria, we re-computed the entire analysis by
using the mutation calls published by TCGA. Out of the
176 driver genes identified by the basic G-2-O algorithm
61 genes were found significant, 61 genes delivered ‘NA’
Fig. 3 A sample analysis result for the AKT1 gene. The plots show the effect of both upregulated genes (a) and downregulated genes (b). Notice
the robust inverse correlation: higher expression of upregulated genes results in worse relapse free survival while lower expression of downregulated
genes also leads to worse survival. High and low: compared to the median of the surrogate gene expression signature
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results, and 54 genes were not significant. The result
was always ‘NA’ in cases when there were fewer than
seven patients with a mutation in the given gene. Of the
61 significant genes, the correlation with survival was
matching for 55 genes, an opposite correlation was ob-
served for six genes. In other words, by introducing the
TCGA thresholds, 65 % of the driver genes were not
identified, mainly because of insufficient number of
genotype alterations.
Computation of expected positive rate
To estimate the expected false positive rate, we per-
formed a random resampling test in which we repeated
the analysis 100 times, each time running the pipeline
on 100 random genes. The mean number of significant
genes was 9.24, none of the runs delivered more than 15
significant genes, and there were at least three genes sig-
nificant in each analysis. The number of runs having a
given number of significant genes is depicted in Fig. 4.
To estimate the number of false positive hits we com-
pared the results (924 hit per 10 k genes) to the number
of COSMIC cancer consensus genes (n = 571) using fol-
lowing formula: FPR = FP/(FP + TN), where FPR = false
positive rate, FP = false positives, TN = true negatives.
The estimated FPR was at 5 % on average (range
0–10 %).
Assessing reproducibility by random holdout
In order to estimate the reproducibility of the results, we
excluded 20 % of the samples at random and re-ran the
entire analysis ten times for a selected set of high preva-
lence genes including 20 top driver candidate genes
(AKT1, PIK3CA, TP53, BRCA2, and so on). Titin (TTN)
was also selected as a non-cancer gene because it has a
high mutation prevalence probably due to its massive
size. Across all analyses, the AKT1 gene upregulated
gene signature had an average hazard ratio of 1.7
(range 1.6–1.8) with an average P value of <1E-16
(<1E-16 – <1E-16), paired with a downregulated gene
signature average hazard ratio of 0.72 (0.59–0.87)
with an average P value of 2.5E-3 (<1E-16–1.4E-2). In
the case of PIK3CA, the upregulated gene signature
hazard ratio was 1.3 (1.2–1.6) with an average P value
of 1.6E-4 (<1E-16–8.8E-4), paired with a downregu-
lated gene signature hazard ratio of 0.64 (0.53–0.7)
with an average P value of 7.2E-12 (<1E-16–4.3E-11).
Table 1 A list of the top 20 most common cancer and non-cancer (based on Cosmic) mutations identified by analyzing 763 breast
cancer samples
Cosmic genesa Non-cosmic genes
Gene % of samples w/ mutations Gene % of samples w/ mutations
FRG1B 58.1 NBPF1 78.2
TTC34 36.5 BAGE2 70.6
PIK3CA 34.6 KMT2C 37.9
CROCC 32.9 BAGE5 34.7
RYR2 30.8 TTN 33.6
TP53 28.1 CROCCP2 33.6
HYDIN 28 MUC16 28.4
NBPF14 24.9 ROCK1P1 23.7
CSF2RA 23.9 TPTE2P6 18.5
PTPRN2 23.9 MST1L 15.9
EIF2B5 23.8 HERC2P4 14.3
PCDHGA1 23.4 MST1P2 14.0
SYNE1 23 DDX12P 13.6
SPDYE3 22.9 DPY19L2P1 12.8
HMCN1 21.2 ANKRD20A9P 11.5
DDX11 20.9 MLLT10P1 11.1
GON4L 20.8 TBC1D3P1-DHX40P1 11.1
PKHD1L1 20.8 MROH7-TTC4 11.0
NEB 20.3 AQP7P1 10.8
USH2A 20.2 SDHAP1 10.6
aVersion: COSMICv71
A significance threshold of 0.01 and a minimal AUC of 0.65 are required for each gene to be considered as significant in the ROC analysis, and the threshold for
significance in the survival analysis was set at P <0.05 and average HR >1.4. This analysis included all genes (including the established driver genes as well)
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Table 2 Analysis results for the top genes including new and already established driver gene candidates. The table is split according
to top 10 oncogene candidates (A) and top 10 tumor suppressor gene candidates (B)
Gene % of samples
w/ mutations
Genes from ROC
analysis (n)
Upregulated genes Downregulated genes
P value HR P value HR
(A)
AKT1 5.5 136 <1E-16 1.8 1.60E-15 0.64
ATG2B 5.1 20 6.70E-09 1.4 6.90E-14 0.66
COL6A2 5.3 151 3.60E-13 1.5 1.50E-09 0.72
MTUS2 5.8 97 6.90E-06 1.3 1.10E-16 0.63
OSBPL10 5.2 46 2.40E-08 1.4 1.80E-12 0.68
POTEF 5.7 16 1.60E-11 1.4 5.60E-16 0.64
SCLT1 5.5 27 3.90E-08 1.4 5.10E-13 0.67
TNC 6 15 1.10E-07 1.3 <1E-16 0.63
TRANK1 5.3 10 <1E-16 1.7 1.90E-05 0.79
TRAPPC10 6.1 3 <1E-16 1.7 2.60E-11 0.69
(B)
ARFGEF1 6.4 63 <1E-16 0.52 <1E-16 1.7
BRCA2 6 74 <1E-16 0.52 2.20E-16 1.6
GGA3 5.5 359 <1E-16 0.49 1.40E-14 1.5
MPP6 5.5 48 <1E-16 0.53 <1E-16 1.8
PHEX 6.6 20 <1E-16 0.47 2.60E-15 1.5
PXDNL 6.1 255 <1E-16 0.51 <1E-16 1.6
RGS22 6 350 <1E-16 0.5 <1E-16 1.7
TP53 28.3 1566 <1E-16 0.48 5.60E-16 1.6
UBR5 9.9 8 <1E-16 0.53 <1E-16 1.7
UNC5D 6.6 51 <1E-16 0.54 <1E-16 1.8
Significant signatures identified had to have an AUC value over 0.65 and a P value below 0.01 in the ROC analysis and an average HR over 1.4 and a P value
below 0.01 in the survival analysis
HR and P value: results of the Cox regression for both up- and downregulated genes
Fig. 4 Distribution of significant hits in random analyses. To assess the expected false positive rate of the method, the entire pipeline was run
100 times each time on 100 randomly selected genes. The mean number of significant genes was 9.24, the number of significant genes was not
more than 15 in any run
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The remaining putative driver genes delivered similar
outcomes, the complete results for all genes are listed
in Additional file 5: Table S4. The TTN gene had no
significant results in any of the analyses.
Finally, we set up the ROC analysis to enable
utilization of different thresholds for accepting a gene as
significant. These include an AUC value between 0.6 and
0.75 and a P value between 0.05 and 0.0001. To estimate
the effect of different cutoffs on classification perform-
ance, we performed the analysis using each available cut-
off (for example, for AUC and P value) combinations for
TP53, PIK3CA, and EGFR. In these analyses, the result-
ing HR and P values showed less than 2 % deviations
(data not shown).
Discussion
We developed a genome-wide approach to link genotype
to clinical outcome by consecutively utilizing next gener-
ation sequencing and gene chip data of 6,697 breast
cancer patients. The two key elements of this system
are: (1) the link between NGS datasets and the well-
annotated gene-chip datasets; and (2) the assumption
that the link is not one-to-one, but includes a set of
genes (transcriptomic fingerprint) indirectly affected by
a somatic mutation. We have set up a web-based system
that enables utilization of the entire analysis pipeline to
assess the correlation between mutational status and
survival for 10,987 genes. Raw data for each of the avail-
able samples were downloaded and re-processed using
the same analysis pipeline to enable robust utilization of
the data. Genes correlated with a given genotype were
identified by employing a ROC analysis across all genes.
Simultaneous utilization of RNA-seq and gene chip as-
says to measure expression of the same genes is sup-
ported by the recent validation of high concordance
between these technologies [28].
While microarray and RT-PCR based assays are lim-
ited to measuring the expression of selected, a priori
chosen genomic features, next generation sequencing
(NGS) technologies are not subject to this limitation and
can be used to evaluate whole genomes, targeted gen-
ome regions, transcriptomes, and epigenomes. A pri-
mary goal of an NGS analysis is the identification of
driver mutations – changes conferring selective advan-
tages to cancer cells and thus contributing to tumor ex-
pansion. However, driver mutations are often buried
inside a cloud of passenger mutations – changes without
biological significance, most likely products of the gen-
omic instability in cancer cells.
As of today, there are no validated drivers of meta-
static disease and drivers of therapy resistance. In
addition, genes imperative for therapy decision including
HER2 (mutation in 1.5 % of samples) and ESR1 (muta-
tion in 0.6 % of samples) show a very low mutational
prevalence. These facts emphasize that many driver
genes are not yet identified. Here, we provide an al-
ternative approach to identify new driver genes. We
hypothesize that by measuring the leveraged effect of
a given mutation on the overall transcriptomic profile
of the tumor the effects of that genomic change can
be evaluated. The utilization of this approach on
already established driver genes confirmed our
method. We have to note that some genes tend to
have high false discovery rate in mutation calling, for
instance HYDIN, SYNE1, and USH2A [29] – it is an
advantage of the proposed methodology is that des-
pite the high mutation rate, none of these genes
reached the significance necessary to be included in
the list of putative driver genes.
A potential limitation of our method is the assumption
that a direct link exists between mutation changes and
gene expression. In fact, a mutation in a driver gene can
be silent without changes in the transcriptional finger-
print – for example activation of certain signaling
pathways like PIK3, which has been shown to be inde-
pendent of changes in expression [30]. Another restric-
tion of our approach is that it cannot be validated for
genes with mutation in a few patients only (low muta-
tion prevalence below 1 %). A further limitation is that
due to lack of data we had to disregard epigenetic effects
on transcription. The same mutation with or without a
methylation event might result in different transcrip-
tional consequences.
We have also computed the expected number of sig-
nificant genes selected at random, which yielded an aver-
age of 9.2 significant genes per 100 randomly picked
genes. This analysis includes a proportion of false posi-
tive hits in addition to the known driver genes (5 % of
all genes based on COSMIC consensus genes). Nonethe-
less, an alternative explanation is that there are still a
large number of unidentified driver genes. Altogether,
the overall number of false positive results is far below
the output of random multigene signatures – 90 % of
which delivered significant association with survival in
breast cancer in a previous study [31]. We have to note
that these random signatures contained more than 100
genes and the G-2-O metagenes contain less than 100
genes in most of the analyses.
Direct analysis on the prognosis of a given mutation
based on the TCGA data is possible using the cBioPortal
[32]. However, shortcomings of the cBio portal include
utilization of overall survival data only, short follow-up,
few death events, and unbalanced cohorts dependent on
prevalence of the mutation. Furthermore, today we know
that breast cancer subtypes carry different sets of
mutations and are linked with different baseline
prognoses – these differences can be easily detected
using the G-2-O analysis platform which enables one
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to investigate the effect on prognosis in each of the
molecular subtypes separately. For example, the haz-
ard ratio associated with a PIK3CA mutation in ER
positive and negative tumors deliver completely dif-
ferent prognostic implications (for the upregulated
gene signature is the HR in ER negative samples
0.66 and HR in ER positive tumors is 1.2).
Previously, an integrated algorithmic approach termed
DriverNet was set up to analyze population-based
genomic and transcriptomic interrogations of a tumor
to identify pathogenic driver mutations [33]. Para-
digm, another similar project was developed to iden-
tify driver pathways [34]. Both of these approaches
were based on incorporating known associations or
interactions between genes. In contrast, the G-2-O
approach is fundamentally different as no recognized
gene or pathway interaction data are included in the
analysis. Rather, the association between genes is re-
computed for each gene in each analysis – this
approach delivers results not influenced by a priori
association networks.
Conclusions
To date, targeting of recognized driver genes deliv-
ered suboptimal results in breast cancer [35]. There
are two major reasons behind this phenomenon –
only a handful of genes are already actionable while
most of these known driver genes have a prevalence
below 10 % of patients. Thus, we need to identify
clinically relevant mutations to spot candidate genes
for targeted therapy or for new personalized clinical
trials. Here, we have set up a pipeline enabling the
functional validation of a discovered mutation for any
gene in a large breast cancer cohort by computation-
ally connecting genotype to an extended, surrogate
gene expression signature and utilizing this signature
in gene chip datasets. Gene chip databases already
serve as transcriptomic basis for cross-dataset analysis
tools like Breast-Mark [36] or the KM-plotter [37].
Since the gene expression datasets are large and rea-
sonably well annotated, we can use the gene expres-
sion surrogate to test the prognostic significance of a
DNA level change. The registration-free, online inter-
face of the Genotype To Outcome (http://www.g-2-
o.com) web server enables researchers, bioinformati-
cians, and clinicians to query the genetic background
of a patient by performing an express evaluation of a
discovered mutation, or combinations of mutations
for any gene.
Endnotes
1Overall survival event available for 87 patients out of
763, median follow-up 487 days. TCGA repository quer-
ied 23 February 2015.
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